MetaCap

Tenax Therapeutics (TENX) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Xilio Therapeutics (XLO) has outperformed Tenax Therapeutics (TENX) over the past year, losing 28.3% versus a loss of 84.7%. Over five years, XLO leads with a -97.3% price change compared with -99.9% for TENX. Tenax Therapeutics is the larger company by market cap ($56.9 million vs $53.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

TENX-84.66%XLO-28.29%
+135%+20%-95%
Nov 21, 20251 yearNov 20, 2026
TENX-99.94%XLO-97.63%
+5%-50%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

TENX versus XLO key metrics
MetricTENXXLO
Share price$1.25$7.56
Market cap$56.92M$53.40M
1-day change-10.07%-1.11%
YTD return-89.75%-15.63%
1-year return-84.66%-28.29%
5-year return-99.94%-97.29%
P/E ratio (TTM)—11.63
EPS (TTM)$-1.39$0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0$43.77M
Revenue growth (YoY)—+589.88%
Net income (latest FY)$-52.60M$-35.04M
Operating margin—-95.92%
Net margin—-80.05%
52-week high$19.40$10.71
52-week low$1.24$6.47
Distance from 52-week high-93.56%-29.41%
Analyst consensusnonenone
Avg. price target upside+904.80%+164.55%
Average volume3.15M11.54K
Shares outstanding45.54M7.06M
Employees1476
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • XLO has outperformed TENX by 56.4 percentage points over the past year.

About Tenax Therapeutics

TENX stock →

Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.

Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

TENX vs XLO FAQ

Which is bigger, Tenax Therapeutics or Xilio Therapeutics?

Tenax Therapeutics (TENX) is larger, with a market capitalization of $56.92M compared with $53.40M for Xilio Therapeutics (XLO).

Which stock has performed better over the past year, TENX or XLO?

XLO returned -28.29% over the past 12 months, compared with -84.66% for TENX (price return, excluding dividends). Past performance does not predict future results.

Are Tenax Therapeutics and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons